Aspergillosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Aspergillosis – Drugs In Development, 2024 report and make more profitable business decisions.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss, and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma, and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungals, and surgery.
The Aspergillosis drugs in development market research report provide comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Aspergillosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 40 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Aspergillosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Aspergillosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Aspergillosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbGenics Life Sciences Pvt LtdAstellas Pharma Inc
Basilea Pharmaceutica Ltd
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
CSPC Pharmaceutical Group Ltd
Evoq Nano Inc
F2G Ltd
Fondation MEDINA
George Papanicolaou Hospital
HC Synthetic Pharmaceutical Co Ltd
Immupharma Plc
Innovation Pharmaceuticals Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Merck & Co Inc
Molecular Express Inc
Nanomerics Ltd
Nob Hill Therapeutics Inc
Pfizer Inc
Pulmatrix Inc
Pulmocide Ltd
Pulmonomy Inc
R-Pharm
Regeneron Pharmaceuticals Inc
Satellos Bioscience Inc
Scynexis Inc
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Stadius Biopharma LLC
Stony Brook University
TFF Pharmaceuticals Inc
The Lundquist Institute
The Walter and Eliza Hall Institute of Medical Research
Trilogy Therapeutics Inc
University of Debrecen
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Aspergillosis reports